Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | GRM5 | P41594 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536679 | 0.91 | KMT2A (0.58) | KMT2AGRM4HDAC6NPC1PKM | |
| SCHEMBL23572370 | 0.81 | KMT2A (0.73) | KMT2ANPC1PKMRAB9AHSD17B14 | |
| SCHEMBL29485024 | 0.81 | KMT2A (0.72) | KMT2ANPC1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL3830943 | 0.81 | KMT2A (0.72) | KMT2ANPC1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL27559411 | 0.81 | MEN1 (0.65) | KMT2ANPC1PKMNFKB1RAB9A | |
| SCHEMBL12441772 | 0.80 | KMT2A (0.66) | KMT2ANPC1PKMNFKB1RAB9A | |
| SCHEMBL7401799 | 0.80 | NPC1 (0.53) | KMT2AGRM4HDAC6NPC1PKM | |
| SCHEMBL30659509 | 0.80 | KMT2A (0.66) | KMT2ANPC1PKMRAB9AHSD17B14 | |
| SCHEMBL22172012 | 0.80 | KMT2A (0.71) | KMT2ANPC1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL8586217 | 0.80 | KMT2A (0.66) | KMT2AHDAC6NPC1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018080065-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2018-05-03 | — | — | WO | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2104677-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2007104696-A1 | ANTIMALARIAL AGENTS HAVING POLYAROMATIC STRUCTURE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | KMT2A 1480/4885GRM4 38/4885HDAC6 1934/4885 |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | AVPR1A, AVPR2, AVPR1B | KMT2A 2040/4885GRM4 634/4885HDAC6 2161/4885 |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | KMT2A 1480/4885GRM4 38/4885HDAC6 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.